P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

Summary

This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic kidney disease (DKD) and proteinuria.

Timeline

Start

2025-06-11

Primary completion

2026-08-11

Completion

2026-08-11

Outcome

Outcome not reported

Stopped (Enrollment): “Withdrawn due to patient enrollment challenges”

Drugs

Indications